HPV cancer vaccine slows tumor growth and extends survival in preclinical model

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure. After proving this concept across multiple studies, the team developed therapeutic cancer vaccines to tackle one of the most challenging targets yet—HPV-driven tumors. In a new study published in the journal Science Advances, the scientists discovered that systematically changing the orientation and placement of a single cancer-targeting peptide can lead to formulations that supercharge the immune system's ability to attack tumors.